Trevi Therapeutics, Inc.

NASDAQ•TRVI

CEO: Ms. Jennifer L. Good

板块: Healthcare

行业: Biotechnology

上市日期: 2019-05-07

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

联系方式

195 Church Street, 16th Floor, New Haven, CT, 06510, United States

203-304-2499

www.trevitherapeutics.com

市值

$1.87B

市盈率 (TTM)

-49.5

18.3

股息率

52周最高

$14.75

52周最低

$5.38

52周范围

98%

排名62Top 92.6%

1.9

F-Score

改良版 Piotroski 分析

基于 9 年期基本面

疲弱 • 1.9 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2017-2025

财务仪表盘

Q4 2025 数据

营业收入

$0.00+0.00%

近4季度走势

每股收益

-$0.06+0.00%

近4季度走势

自由现金流

$5.85M+0.00%

近4季度走势

2025 Annual 财报亮点

核心亮点

Net Loss Narrows Significantly Net loss decreased $5.2M to $42.8M for 2025, reflecting reduced R&D spending versus prior year.

Strong Cash Position Maintained Cash and marketable securities reached $188.3M by year-end 2025, funding operations into 2028.

Positive Cough Trial Results Phase 2b CORAL trial achieved primary endpoint showing significant 24-hour cough frequency reduction.

Phase 3 Trials Scheduled FDA alignment secured; first pivotal Phase 3 trial for IPF-related cough set to initiate Q2 2026.

关注风险

Continued Operating Losses Expected Significant losses incurred since inception; substantial additional capital required to fund operations beyond 2028.

Sole Product Candidate Dependency Business success entirely dependent on Haduvio development, approval, and commercialization success across indications.

Clinical Trial Design Uncertainty Trial outcomes are uncertain; regulatory changes or enrollment difficulties could delay approval or increase costs.

Opioid Class Label Warning Nalbuphine carries opioid class warning; potential restrictive marketing/distribution regulations could harm profitability.

前瞻展望

Initiate Pivotal Phase 3 Studies Plan to initiate two pivotal Phase 3 trials for IPF chronic cough starting Q2 2026, running in parallel.

Expand Chronic Cough Development Adaptive Phase 2b trials planned for non-IPF ILD and RCC indications starting second half of 2026.

Complete NDA Supportive Testing Progressing remaining Phase 1 NDA supportive studies, including respiratory safety assessment, targeting completion mid-2026.

Maintain Intellectual Property Focus remains on maintaining, expanding, and protecting proprietary patent portfolio across key territories globally.

同行对比

营业收入 (TTM)

NVAX

$1.12B

+64.7%

ARDX

$407.32M

+22.1%

SNDX

$172.35M

+627.8%

毛利率 (最新季度)

SNDX

102.3%

-13.9pp

NBTX

100.0%

+0.0pp

IMTX

100.0%

+0.0pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
TERN	$4.75B	-51.0	-20.0%	0.1%
SYRE	$4.21B	-155.4	-29.4%	0.0%
SNDX	$2.10B	-7.2	-206.6%	65.4%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

N/M

营收波动较大

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

现金流需要关注

深度研究

下次财报:2026年5月6日

每股收益:-

营业收入:-

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据